Are you heading to the American Society of Interventional Pain Physicians (ASIPP) 2024 meeting in Dallas, TX? If so, make sure to join us at our dinner reception and hear from Drs. Chris Beuer, Anjum Bux and Tammy Dann on how to grow and differentiate your practice using a modern approach to targeted drug delivery (TDD). Don't miss out! Make sure to register for our Targeted Drug Delivery Reception and Dinner: https://bit.ly/3VDQaHz Stop by our booth to learn about the broad Medtronic product portfolio! #MDTPainInterventions #ASIPP2024
Medtronic Pain Interventions’ Post
More Relevant Posts
-
People with pulmonary sarcoidosis are being invited to take part in a clinical trial at Cambridge University Hospitals NHS Foundation Trust. The RESOLVE-Lung study is evaluating the safety and effectiveness of a new drug, namilumab. If successful, it will provide an alternative option to steroids. Read the full story: https://lnkd.in/ebdbHnEW #Sarcoidosis #PulmonarySarcoidosis #CambridgeResearch #NIHR #ClinicalResearch #HealthResearch #BePartOfResearch
To view or add a comment, sign in
-
On May 1st, I’m presenting a webinar (ACPE accredited for 1.0 CE!) with the ASHP Section of Ambulatory Care Practitioners SAG on Ambulatory Care Pharmacotherapy called: 🚨A LDL Bit Goes a Long Way: Navigating Statin and Non-Statin Therapies 🚨 Register here! https://lnkd.in/g8NAVVn9 This presentation will review the most recent guidelines regarding lipid management from the perspective of different professional organizations. Similarities and differences between these guidelines will be highlighted and discussed. Additionally, newer non-statin medications will be described. Lastly, patient cases will be presented to apply guideline recommendations.
To view or add a comment, sign in
-
🏥 Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXess, its restorative vascular access conduit Xess is a restorative conduit that enables the creation of a new, permanent, living vessel for hemodialysis vascular access, combining the safety and patency of an arteriovenous fistula (AVF), with the speed to treatment of an arteriovenous graft (AVG). The aXess vascular access conduit offers an improved dialysis patient experience and avoids the frequent reinterventions and complications, such as infections, faced by many renal disease patients. Xeltis’ novel technology has already treated over 100 patients across different clinical trials. Read more online: https://lnkd.in/eQY5EH7S 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing
To view or add a comment, sign in
-
🔍 Dive into clinical insights! New study reveals how standardisation in clinical trial design can enhance the validity of trial data for diabetic foot ulcers. 📊 Discover the key findings and implications for future research in wound care. Download a PDF copy: https://bit.ly/4cb0Kvl #ClinicalResearch #DiabeticFootUlcers #WoundHealing #ClinicalTrials #DFU #NATROXO2
To view or add a comment, sign in
-
This detailed slide deck of the latest study by Afif, et al. shows the final efficacy and safety results of the UNIFI LTE study through 4 years. They found that long-term subcutaneous therapy with ustekinumab in patients who responded to intravenous ustekinumab was safe and effective at maintaining symptomatic remission. You can find the full paper summary on the IMID Forum completely free along with the latest updates in #Crohn’sDisease https://ow.ly/UqCk50SiKsq
To view or add a comment, sign in
-
US HCPs: 🚨 STRIDE data introduces a new standard of care for patients with acute limb ischemia (ALI) by demonstrating clinical advantages to the traditional open surgical approach. #CAVT #LightningBolt7 Rx only. Risk info: peninc.info/risk Clinical results may vary
To view or add a comment, sign in
-
The Myeloma and AL Amyloidosis European Clinical Trial Navigator is a powerful online tool by Myeloma Patients Europe (MPE). This platform helps you find clinical trials for myeloma, MGUS, smouldering myeloma (SMM), and AL amyloidosis across Europe. For patients, the tool supports informed discussions with healthcare professionals on trial options and empowers advocates to push for better clinical trial access at national levels. Learn more in the link below https://lnkd.in/dDRHsv2Z #MyelomaAdvocacy #ClinicalTrials #MPE #MPENavigator #EuropeanMyelomaDay
To view or add a comment, sign in
-
In this cohort study with up to 5 years of follow-up, dupilumab maintained its clinical effectiveness, while two-thirds of patients tapered to a dosing interval of every 3 or 4 weeks. https://ja.ma/3yCtPRu
To view or add a comment, sign in
-
Here at BIOHIT, we offer ways to tailor patient care with our range of #TherapeuticDrugMonitoring (TDM) assays. TDM measures specific drugs in a patient's bloodstream over time. This helps guide individualised care plans for patients living with #ChronicInflammatoryDiseases. Our TDM assays allow clinicians to assess treatment responses, anticipate outcomes and enhance patient care. View the full range here: https://ow.ly/2MrY50RyI5n #GastroHealth #ChronicDisease
To view or add a comment, sign in
-
Heartbeats Highlights: *A DUE trial* Fixed-Dose Macitentan/Tadalafil Combo Gets FDA Approval for PAH FDA approved macitentan/tadalafil (Opsynvi) today (03/25/2024) as the first single-tablet combination therapy targeting multiple pathways for pulmonary arterial hypertension (PAH). A study of 187 people in WHO functional class II or III that showed that dual macitentan/tadalafil reduced pulmonary vascular resistance nearly 30% more than macitentan and tadalafil monotherapy by week 16. #Cardiovascular #interventionalCardiology #cardiacImaging #heartfailure
ClinicalTrials.gov
clinicaltrials.gov
To view or add a comment, sign in
18,403 followers